"10.1371_journal.pone.0147821","plos one","2016-01-25T00:00:00Z","Donna E. Sweet; Frederick L. Altice; Calvin J. Cohen; Björn Vandewalle","Internal Medicine, The University of Kansas School of Medicine–Wichita, Wichita, Kansas, United States of America; Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, United States of America; CRI New England, Boston, Massachusetts, United States of America; Exigo Consultores, Lisbon, Portugal","Conceived and designed the experiments: DES FLA CJC BV. Performed the experiments: BV. Analyzed the data: BV. Contributed reagents/materials/analysis tools: BV. Wrote the paper: DES FLA CJC BV.","Frederick L. Altice has declared the following competing interests: Speakers Bureau – Merck, Bristol-Myers Squibb (BMS), Rush Simply Speaking HIV, Practice Point Communications; Research/grant support – Gilead, Merck, Elton John Foundation, NIHNIDA, NIAAA, SAMHSA, HRSA; Consultant – Gilead, Merck, BMS. Calvin J. Cohen has declared the following competing interests: Research and grant support – Gilead, Janssen; Advisory Board honoraria – Gilead, BMS, Janssen, Merck, Viiv. Björn Vandewalle has declared that no competing interests exist. Donna E. Sweet has declared the following competing interests: Speakers Bureau – Gilead, BMS, AbbVie; Research – Merck; Consultant – Gilead, Pfizer. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2016","01","Donna E. Sweet","DES",4,FALSE,4,1,1,4,TRUE,FALSE,FALSE,0,NA,FALSE
